# US 2023/0055657 A1 · Combination treatment of liver diseases using integrin inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0055657 A1
- Document ID: US20230055657A1
- Status: Published application
- Kind: A1
- Application number: 17/786,499
- Filed: 2020-12-18
- Published: 2023-02-23
- Earliest claimed: 2019-12-20
- Assignees: Novartis AG; Pliant Therapeutics, Inc.
- Applicants: Novartis AG; Pliant Therapeutics, Inc.
- Inventors: Kraig ANDERSON; Christopher BAILEY; Avirup BOSE; Jacob CHA; Nicole COOPER; Darren FINKELSTEIN; Linda GREENBAUM; Johannes HULL; Susan Caroline KIRKLAND; Katerina LEFTHERIS; Maureen REILLY; Peter TARSA; Chinweike UKOMADU
- Web page: https://patentgrep.com/patent/US20230055657A1

## CPC

- A61K 31/46: 8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
- A61K 31/4353: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides a pharmaceutical combination including an αvβ1 integrin inhibitor and at least one additional therapeutic agent for preventing, delaying or treating liver diseases or disorders. The at least one additional therapeutic agent may be a farnesoid X receptor (FXR) agonist. For example, the pharmaceutical combination includes (S)-2-(4-methyltetrahydro-2H-pyran-4-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid (Compound 1) and 2-[3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1, 3-ben-zothiazole-6-carboxylic acid (tropifexor).

## Claims

### Claim 1

A pharmaceutical combination comprising 1) an αvβ1 integrin inhibitor and 2) at least one additional therapeutic agent, for simultaneous, sequential or separate administration.

### Claim 2 (depends on 1)

The pharmaceutical combination of claim 1, wherein the αvβ1 integrin inhibitor is (S)-2-(4-methyltetrahydro-2H-pyran-4-carboxamido)-9-(5,6,7,8-tetrahydro-1,8-naphthyri din-2-yl)nonanoic acid, a stereoisomer, a tautomer, an enantiomer, a pharmaceutically acceptable salt, a prodrug, an ester, or an amino acid conjugate thereof.

### Claim 3 (depends on 1, 2)

The pharmaceutical combination of claim 1 or 2, wherein the at least one additional therapeutic agent is a non-bile acid derived FXR agonist that is 2-[(1R,3r,5S)-3-({5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl}methoxy)-8-azabicyclo[3.2.1]octan-8-yl]-4-fluoro-1,3-benzothiazole-6-carboxylic acid, a pharmaceutically acceptable salt, prodrug, ester, or an amino acid conjugate thereof.

### Claim 4 (depends on 1, 2, 3)

The pharmaceutical combination of any of claims 1 to 3, wherein the pharmaceutical combination is a fixed dose combination.

### Claim 5 (depends on 1, 2, 3)

The pharmaceutical combination of any of claims 1 to 3, wherein the pharmaceutical combination is a free combination.

### Claim 6 (depends on 1, 2, 3, 4, 5)

Use of the pharmaceutical combination of any one of claims 1 to 5, in the manufacture of a medicament for preventing, delaying or treating a liver disease or disorder.

### Claim 7 (depends on 6)

The use of claim 6, wherein the liver disease or disorder is fibrotic or cirrhotic liver disease or disorder.

### Claim 8 (depends on 1, 2, 3, 4, 5)

A method of preventing, delaying or treating a liver disease or disorder, in a patient in need therefor, comprising administering a therapeutically effective amount of the pharmaceutical combination of any of claims 1 to 5.

### Claim 9 (depends on 8)

The method of claim 8, wherein the liver disease or disorder is a fibrotic or cirrhotic liver disease or disorder, selected from the group consisting of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver cirrhosis, alcohol-induced cirrhosis, cystic fibrosis-associated liver disease (CFLD), liver fibrosis, and progressive fibrosis of the liver caused by any of the diseases above or by infectious hepatitis.

### Claim 10 (depends on 8)

The method of claim 8, wherein the liver disease or disorder is non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), liver fibrosis, or liver cirrhosis.
